Evidence map›Paper›PMID 37450093›Full record

Trial reportAnnals of surgical oncology2023

A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).

Shin Kobayashi, Masafumi Ikeda, Kohei Nakachi, Makoto Ueno, Takuji Okusaka, Akiko Todaka, Sohei Satoi, Akira Tomokuni, Masaru Konishi, Junji Furuse

Erratum issuedAbstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Shin KobayashiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan. shkobaya@east.ncc.go.jp.ORCID http://orcid.org/0000-0001-9321-8452
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kohei NakachiDepartment of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Akiko TodakaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Sohei SatoiDepartment of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Akira TomokuniDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Masaru KonishiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
National Cancer Center Hospital East · JPKanagawa Prefectural Hospital Organization · JPKansai Medical University · JPKyorin University · JPOsaka International Cancer Institute · JPShizuoka Cancer Center · JPTochigi Cancer Center · JP

Funding

Japan Agency for Medical Research and Development 16ck0106079h0003Japan Agency for Medical Research and Development 17ck0106350h0001Ministry of Health, Labour and Welfare H26-076National Cancer Center Japan 23-A-22National Cancer Center Japan 26-A-4National Cancer Center Japan 29-A-3
6 · The paper itself

Abstract

backgroundThe Adjuvant S-1 for Cholangiocarcinoma Trial (JCOG1202, [ASCOT]) was a multicenter, randomized controlled trial aimed at investigating the efficacy and safety of adjuvant chemotherapy (AC) with S-1 for resected biliary tract cancer (BTC). This trial reported that overall survival was prolonged with AC compared with observation.

methodsWith the aim of increasing enrollment, the present survey biannually recorded the number of patients eligible for enrollment into ASCOT and reasons for ineligibility among patients who had undergone surgery for BTC from April 2015 to September 2017 at 36 institutions participating in ASCOT.

resultsOf 2039 patients who underwent surgery for BTC, 211 (10.3%) were already enrolled, 166 (8.1%) were eligible but had not been enrolled, and 1662 (81.5%) were ineligible. Among ineligible patients, the predominant reasons for ineligibility were patient refusal (n = 332, 20.0%), pathologic stage (pT1N0; n = 248, 14.9%), age (≥ 81 years; n = 196, 11.8%), and prolonged postoperative complications (n = 176, 10.6%).

conclusionsPatients undergoing surgery for BTC are a heterogeneous cohort comprising patients with earlier pathologic stage, advanced age, and prolonged postoperative complications. These factors should be considered during the design of future clinical trials of perioperative treatments for resectable BTC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBiliary Tract NeoplasmsCholangiocarcinomaPatient SelectionAgedAged, 80 and overChemotherapy, AdjuvantDrug CombinationsFemaleFollow-Up StudiesHumansMaleMiddle AgedOxonic AcidPrognosisDrug CombinationsOxonic AcidS 1 (combination)TegafurAdjuvant chemotherapyBiliary tract cancerEligibilityRandomized controlled trialSurgery

Identifiers

PMID37450093
OpenAlexW4384339638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.